These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15388831)

  • 1. Labile iron in parenteral iron formulations: a quantitative and comparative study.
    Coyne DW
    Nephrol Dial Transplant; 2004 Oct; 19(10):2674-5; author reply 2675-6. PubMed ID: 15388831
    [No Abstract]   [Full Text] [Related]  

  • 2. Parenteral iron therapy: indications and safety.
    Marwaha RK; Trehan A
    Indian Pediatr; 1997 Mar; 34(3):261-2. PubMed ID: 9282501
    [No Abstract]   [Full Text] [Related]  

  • 3. [Iron metabolism disorders].
    Bommer M; Heimpel H
    Pharm Unserer Zeit; 2009; 38(3):242-50. PubMed ID: 19396907
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessing iron status: beyond serum ferritin and transferrin saturation.
    Wish JB
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S4-8. PubMed ID: 17699374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence that stainable bone marrow iron following parenteral iron therapy does not correlate with serum iron studies and may not represent readily available storage iron.
    Thomason RW; Almiski MS
    Am J Clin Pathol; 2009 Apr; 131(4):580-5. PubMed ID: 19289594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CE characterization of potential toxic labile iron in colloidal parenteral iron formulations using off-capillary and on-capillary complexation with EDTA.
    Jahn MR; Mrestani Y; Langguth P; Neubert RH
    Electrophoresis; 2007 Jul; 28(14):2424-9. PubMed ID: 17577885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of disorders of iron metabolism].
    Pinggera W
    MMW Fortschr Med; 2004 Nov; 146(48):37-8, 40. PubMed ID: 15625935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron formulations in pediatric practice.
    Nagpal J; Choudhury P
    Indian Pediatr; 2004 Aug; 41(8):807-15. PubMed ID: 15347868
    [No Abstract]   [Full Text] [Related]  

  • 9. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
    Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
    Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-valent iron intermediates in biology.
    Ghosh A
    J Inorg Biochem; 2006 Apr; 100(4):419-20. PubMed ID: 16584953
    [No Abstract]   [Full Text] [Related]  

  • 11. A common cause of pruritus in dialysis patients.
    Jenkins P
    Am J Kidney Dis; 2008 Feb; 51(2):345; author reply 345-6. PubMed ID: 18215714
    [No Abstract]   [Full Text] [Related]  

  • 12. Periodic iron nanomineralization in human serum transferrin fibrils.
    Ghosh S; Mukherjee A; Sadler PJ; Verma S
    Angew Chem Int Ed Engl; 2008; 47(12):2217-21. PubMed ID: 18256996
    [No Abstract]   [Full Text] [Related]  

  • 13. Parenteral iron therapy is associated with a characteristic pattern of iron staining on bone marrow aspirate smears.
    Thomason RW; Lavelle J; Nelson D; Lin K; Uherova P
    Am J Clin Pathol; 2007 Oct; 128(4):590-3. PubMed ID: 17875510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular labile iron modulates adhesion of human monocytes to human endothelial cells.
    Kartikasari AE; Georgiou NA; Visseren FL; van Kats-Renaud H; van Asbeck BS; Marx JJ
    Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2257-62. PubMed ID: 15486315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioactive properties of iron-containing carbon monoxide-releasing molecules.
    Sawle P; Hammad J; Fairlamb IJ; Moulton B; O'Brien CT; Lynam JM; Duhme-Klair AK; Foresti R; Motterlini R
    J Pharmacol Exp Ther; 2006 Jul; 318(1):403-10. PubMed ID: 16603670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
    Devanur LD; Evans RW; Evans PJ; Hider RC
    Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supporting epoetin alfa stimulated erythropoiesis: identifying appropriate iron levels: case study of the anemic patient.
    Sasak C
    Nephrol Nurs J; 2000 Dec; 27(6):612-5. PubMed ID: 16649342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The comparison of diagnostic usefulness of transferrin determination by immunological and chemical method in iron deficiency anemia].
    Krawiec A; Cylwik B; Chrostek L; Szmitkowski M
    Pol Merkur Lekarski; 2007 Mar; 22(129):173-6. PubMed ID: 17682669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular labile iron.
    Breuer W; Shvartsman M; Cabantchik ZI
    Int J Biochem Cell Biol; 2008; 40(3):350-4. PubMed ID: 17451993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A trispyrazolylborato iron cysteinato complex as a functional model for the cysteine dioxygenase.
    Sallmann M; Siewert I; Fohlmeister L; Limberg C; Knispel C
    Angew Chem Int Ed Engl; 2012 Feb; 51(9):2234-7. PubMed ID: 22287034
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.